Summary of new 8K just filed
$Mangoceuticals (MGRX.US)$ On October 21, 2024, Mangoceuticals, Inc., also known as MangoRx, issued a press release to address and counter public claims made by pharmaceutical giant Eli Lilly. The claims pertain to allegations that MangoRx improperly replicated Eli Lilly's weight-loss medication, Zepbound and Mounjaro. MangoRx, listed on NASDAQ under the ticker MGRX, has categorically denied these allegations and has expressed its intention to vigorously defend itself against the lawsuit filed by Eli Lilly. The company emphasized its commitment to providing safe and effective products to patients deemed medically appropriate by licensed U.S. practitioners. MangoRx, which specializes in men's health and wellness products delivered through a telemedicine platform, highlighted its ongoing mission to offer innovative solutions while adhering to regulatory guidelines. The press release also contained forward-looking statements regarding the company's future plans and addressed potential risks and uncertainties that could impact its operations and financial performance.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
J L 7 2 : Plagiarism crime! No wonder it dropped so much yesterday.